CLINICAL_TRIALS
trial_result
· 2021-06-18
Clinical Trial Update: Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Summary
Phase 2 study of oral LBH589 in adults with refractory/resistant cutaneous T-cell lymphoma (CTCL) was terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cutaneous T-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2021-06-18